-- The 2025 DREAMS Grant Program awards $50,000 each to two non-profit organizations working to advance equity, accessibility and inclusion for those living with Duchenne in the U.S., EU or U.K. -- -- Announced in advance of World Duchenne Awareness Day on September 7, grants are designed to fund projects supporting the Duchene community on a global scale -- BOSTON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the recipients of its third annual DREAMS Grant Pr ...

Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to earnings of $1.55 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -20.93%. A quarter ago, it was expected that this company would post a loss of $0.78 per share when it actually produced a loss of $0.42, delivering a surprise of +46.15%.Over the last four quarters, the com ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ FORM 10-Q ____________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-40969 ____________________ ...

Entrada Therapeutics Reports Second Quarter 2025 Financial Results -- First patient dosed in ELEVATE-44-201 with data from first patient cohort anticipated in H1 2026 -- -- Initiated ELEVATE-45-201 and on track to dose the first patient in Q3 2025 -- -- Multiple clinical trial sites in U.K. and EU activated for ELEVATE-44-201 and ELEVATE-45-201 -- -- Leadership team expanded with the additions of Navid Khan, PhD, as Senior Vice President of Medical Affairs and Kiran Patki, MD, MSc, FFPM, as Senior Vice Pres ...

Corporate Presentation August 2025 Disclaimer This presentation has been prepared by Entrada Therapeutics, Inc. (the "Company") and shall not constitute an offer to sell or a solicitation of an offer to buy securities or an invitation or inducement to engage in investment activity nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of such securities under the securities law of any such jurisdiction. ...

Entrada Therapeutics, Inc. (TRDA) shares ended the last trading session 5.6% higher at $6.64. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 11.5% loss over the past four weeks. The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> The sudden price rise can be attributed to growing investor optimism related to the company's lead oli ...

Company Overview and Pipeline - Entrada Therapeutics expects to have four active clinical programs by the end of 2025[4, 15] - The company has a strong financial position with approximately $383 million in cash, providing a cash runway into Q2 2027[5] - The company's pipeline includes programs for Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1), with partnered product VX-670 for DM1[14] - Entrada's Endosomal Escape Vehicle (EEV) technology aims for approximately 50% endosomal escape, compared to the standard approximately 2%[11] DMD Program Updates - ENTR-601-44: Clinical studies are authorized in the UK, EU, and US, with Phase 1/2 MAD study initiation expected in Q2 2025[4, 36, 46] - ENTR-601-45: Clinical study is authorized in the UK and EU, with Phase 1/2 MAD study initiation expected in Q3 2025[4, 38, 53] - ENTR-601-50: The company is on track to submit global regulatory filings in H2 2025, with Phase 1/2 MAD initiation expected in Q4 2025[4, 42, 65] - ENTR-601-44 Phase 1 data showed strong clinical safety up to 6 mg/kg, with potential for best-in-class pharmacokinetics and pharmacodynamics[19, 20] ENTR-601-44 Phase 1 Data Highlights - No treatment-related adverse events were reported in the ENTR-601-44-101 study up to the highest dose of 6 mg/kg[20] - At a dose of 6 mg/kg of ENTR-601-44, robust target engagement with statistically significant exon skipping was observed versus placebo[31]

Summary of Conference Call on Entrada Therapeutics Company Overview - **Company Name**: Entrada Therapeutics - **Founded**: 2016 - **Focus**: Development of therapies for Duchenne muscular dystrophy (DMD) using a platform based on small cyclic peptides [4][3] Key Points and Arguments Technology and Platform - Entrada's platform utilizes a library of small cyclic peptides (8-10 kD) that facilitate drug delivery through endocytosis, significantly improving the therapeutic index by increasing the amount of drug that reaches intracellular targets [5][6] - The platform has demonstrated a 50% escape rate from endosomes compared to the industry average of 1-2%, allowing for more effective drug delivery [6][7] DMD Programs - Entrada is advancing multiple DMD programs, including ENTR 601-44 and ENTR 601-45, which have received regulatory clearance for clinical trials in the EU, UK, and the US [7][11] - The company has shown promising results in preclinical models, including significant exon skipping and dystrophin production in knockout mouse models [7][9] - A healthy volunteer trial demonstrated safety at the highest dose with no clinically relevant adverse events, indicating a strong pharmacokinetic profile [10][20] Competitive Landscape - Entrada positions itself as a leader in the DMD space by focusing on producing higher levels of functional dystrophin compared to existing therapies, including exon skippers and gene therapies [12][14] - The company emphasizes the importance of both the quantity and quality of dystrophin produced, which correlates with better functional outcomes for patients [33][34] Clinical Development Strategy - Entrada is targeting underserved adult DMD patients, who represent 40-50% of the market but are often overlooked in clinical trials [24][27] - The company plans to conduct adaptive trials, adjusting doses based on patient responses and safety data [24][26] Market Evolution - The DMD market is expected to evolve towards a polypharmacy approach, where multiple therapies are used in combination to optimize patient outcomes [32][37] - Entrada anticipates that as gene therapies and other modalities become available, there will be a need for complementary treatments that enhance dystrophin production and muscle regeneration [34][35] Future Outlook - Entrada is optimistic about the upcoming years, with significant milestones expected as clinical trials progress and data from various programs become available [38][41] - The company is also exploring partnerships to expand its capabilities and accelerate program development, similar to its collaboration with Vertex Pharmaceuticals [45][46] Additional Important Content - The company has not observed liver toxicity issues with its PMO-based chemistry, which is a concern for other therapeutic modalities [20][21] - Entrada's approach to DMD treatment is centered on improving quality of life for patients, focusing on both dystrophin production and functional metrics related to daily living [28][29] This summary encapsulates the key insights from the conference call regarding Entrada Therapeutics, its innovative platform, ongoing clinical programs, competitive positioning, and future strategies in the biotechnology sector focused on DMD.

Summary of Entrada Therapeutics (TRDA) 2025 Conference Call Company Overview - **Company**: Entrada Therapeutics (TRDA) - **Focus**: Development of intracellular therapeutics targeting neuromuscular diseases, specifically Duchenne muscular dystrophy (DMD) and myotonic dystrophy type one (DM1) [2][7] Key Clinical Programs - **Active Clinical Programs**: By the end of 2025, the company expects to have four active clinical programs [2] - **Duchenne Muscular Dystrophy (DMD) Franchise**: - **ENTR-601-44**: Clinical studies authorized in the UK, US, and EU; currently enrolling [3] - **ENTR-601-45**: Regulatory clearance obtained; clinical trial enrollment to begin [3] - **ENTR-601-50**: Regulatory submission expected in the second half of 2025 [4] - **Myotonic Dystrophy Type One (DM1)**: Collaboration with Vertex on VX-670; ongoing global study with 26 clinical sites [5] Financial Position - **Cash Position**: Approximately $383 million on the balance sheet, providing a cash runway into Q2 2027 [6][37] - **Importance of Cash**: Financial stability allows the company to navigate critical clinical data points and potential inflection points [6][37] Therapeutic Approach - **Intracellular Targets**: 75% of disease-causing targets are intracellular, which presents significant opportunities for the company [8][11] - **Endosomal Escape Vehicles (EEVs)**: Utilization of cyclic cell-penetrating peptides to enhance cellular uptake and improve therapeutic delivery [8][9] Clinical Data and Safety - **Phase 1 Study for ENTR-601-44**: - Conducted with 32 subjects (24 active, 8 placebo); demonstrated strong clinical safety with no treatment-related adverse effects [17][19] - Dose-dependent increase in plasma concentration observed, indicating a broad therapeutic window [21] - **Future Studies**: Plans to run a global two-part study for ENTR-601-44 and ENTR-601-45, focusing on safety, tolerability, and efficacy [28][30] Market Opportunity - **Duchenne Muscular Dystrophy**: Over 40,000 individuals affected in the US and Europe, highlighting a significant unmet clinical need [27] - **Pipeline Expansion**: Potential to explore ocular programs and other diseases beyond neuromuscular conditions [34][37] Conclusion - **Outlook**: The company is positioned for a busy 2025 and beyond with multiple clinical studies and a strong financial foundation, aiming to address significant unmet needs in neuromuscular diseases and potentially expand into other therapeutic areas [35][37]

Company Overview - Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of medicines that target intracellular mechanisms previously deemed inaccessible [4] - The company utilizes its proprietary Endosomal Escape Vehicle (EEV™) technology to enhance the intracellular delivery of therapeutics, aiming to improve therapeutic indices across various diseases [4] Recent Developments - The company announced the appointment of Dr. Maha Radhakrishnan to its Board of Directors, which is expected to bolster its clinical momentum, particularly in the Duchenne muscular dystrophy franchise [1][2] - Dr. Radhakrishnan brings extensive experience in global drug development, having previously held senior roles at Biogen and Sanofi, which will be instrumental as Entrada advances its clinical-stage portfolio [3] Clinical Focus - Entrada is advancing multiple patient-focused clinical trials for its Duchenne muscular dystrophy programs throughout the year, with promising Phase 1 safety and target engagement data [2][3] - The company is developing lead oligonucleotide programs targeting exon 44, 45, 50, and 51 skipping for the treatment of Duchenne muscular dystrophy [4]